Results 71 to 80 of about 30,618 (276)

ACKR1/Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough, Oriella Stellakis, Daisy Mills, Blanca Bjourson, Vicky Chaplin, Dharmisha Chauhan, Bev Chipp, Marius Cotic, Jana de Villiers, Olubanké Dzahini, Frances Elmslie, Katie Evans, Shreyans Gandhi, Dyfrig A. Hughes, Huajie Jin, Daniele Panconesi, Anna Skowronska, Sanjay M. Sisodiya, Ed Silva, Vicky Stinton, Sara Stuart‐Smith, Sarah Tarrant, David Taylor, Lauren Varney, James T. R. Walters, Michelle Wood, Jessica Woodley, Cinzia Dello Russo, Munir Pirmohamed, Elvira Bramon   +29 more
wiley   +1 more source

The Effects of Pharmacogenetics on Pharmacokinetics\ud of Artemisinin-Based Combinations in Malaria Patients [PDF]

, 2009
Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become life-threatening, leading to an estimated 900’000 annual deaths globally. Key
Hodel, Eva Maria
core  

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong, Jungryul Kim, Woojin Jung, Jiyeon Jeon, Hyeongjun Jo, Kyoung‐Bin Ryu, Ja‐Young Hong, Kwan Soo Kim, Seongjun Yang, Hee Young Ju, Hwi‐yeol Yun, Jung‐woo Chae, Keon Hee Yoo, Soyoung Lee   +13 more
wiley   +1 more source

The association between white blood cell count and relative risk of non-small cell lung cancer

Discover Oncology
Background High abundance of eosinophils has been proved to associated with favorable disease progression in non-small cell lung cancer (NSCLC) in the previous observational studies, but the causal relationship remains unclear. It is also unclear whether
Xiao Yang, Wenyi Liu, Jiaqi Wang, Weifeng Xia, Lanxiang Wu   +4 more
doaj   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Pharmacogenetics and Stroke [PDF]

Stroke, 2009
Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin.
openaire   +2 more sources

Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development

BioTechniques, 2005
Pharmacogenetics and pharmacogenomics are keys to the success of personalized medicine, prescribing drugs based on a patien's individual genetic and biological profile.
Li Yan, Robert A. Beckman
doaj   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

UHPLC–MS/MS Method for the Simultaneous Quantification of 12 Antiretroviral Drugs in Human Plasma Using Dried Sample Spot Devices: Development, Validation, and Stability Evaluation

Pharmaceutics
Background/Objectives: In several contexts, Dried Sample Spot Devices (DSSDs) offer a convenient and safe alternative for sampling, storage, and shipment, allowing the transport and storage of biological samples at room temperature, reducing shipment ...
Sara Soloperto, Elisa Martina, Alice Palermiti, Elisa Barnini, Greta Sabbia, Gianluca Bianco, Martina Billi, Camilla Martino, Alessandra Manca, Marco Simiele, Jessica Cusato, Antonio D’Avolio, Amedeo De Nicolò   +12 more
doaj   +1 more source